Global Biosimilars Market By Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), By Region, Industry Analysis, Share, Growth, Trends, and Forecast, 2021-2028

Covid-19 Impact on Global Biosimilars Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC214007

No. of Pages : 375

The global biosimilars market is expected to grow from USD 163.2 billion in 2020 to USD 381.5 billion by 2028 at a CAGR of 11.2 % over the forecast period 2021-2028.

Market Overview:

A biosimilar is a biologic medical product, and biologic is a drug sourced from proteins (artificial or natural). Biosimilar drug is made in a living system such as yeast, bacteria, or animal cells. Biosimilars are approved with equivalent pharmaceutical quality, safety, and efficacy standards that apply to all or any biological medicines. These drugs stimulate the body's system to effectively acknowledge and kill cancer cells and prevent cancer cells' growth.

The growing prevalence of chronic diseases is the primary factor which is boosting the global biosimilar market growth and development in the present scenario.

Market Dynamics:

Drivers:

Increasing demand for biosimilar drugs

Rising incidence of chronic diseases

Restraints:

Unavailability of definitive standards for approval and profitability

Risks & concerns regarding substitutability and interchangeability

Key Market Players:

Pfizer, Sandoz, Biocon, Fresenius Kabi AG, Boehringer Ingelheim, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Amega Biotech, mAbxience, Probiomed, Apotex, Gedeon Richter, Biocad, Coherus Bioscience, and Stada Arzneimittel AG are some of the prominent players in the global biosimilars market.

The market is segmented based on the below-mentioned segments:

On the Basis of Product Type: Revenue

o Insulin

o Interferon

o Etanercept

o Infliximab

o Rituximab

o Glucagon

o Calcitonin

On the Basis of Manufacturing: Revenue

o In-house

o Contract

On the Basis of Indication: Revenue

o Oncology

o Chronic Disease

o Blood Disorder

o Autoimmune Disease

On The Basis of Region: Revenue

North America

- U.S.A
- Canada
- Mexico

Europe

- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

Asia Pacific

- China
- Japan
- India
- SEA
- Australia
- Rest Of APAC

South America

- Brazil
- Argentina
- Rest of South America

Middle East & Africa

- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Report Description

Year Consideration
- Base year – 2020
- Historic Year-2017-2019
- Forecast year- 2021 to 2028

The global biosimilars market will be based on revenue and volume. The study covers the market share for segments, countries, regions, and players.

The regions evaluated for the global biosimilars market are Europe, North America, Asia Pacific, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country-level.

The report provides an in-depth pricing analysis, value chain analysis, industry road map, and micro and macro factors.

The research report further provides the attractiveness of biosimilars and regions based on their growth rate (CAGR), market size, and attractiveness by analyzing present and future prospects to analyze market growth and development in the future.

Also, the study focuses on market-related driving forces, restraints, potential opportunities for the market, significant developments, and advancement that serve as a key potential for investors.

The study offers an extensive evaluation of Porter's five forces analysis, SWOT analysis, and PESTEL analysis to provide data and information related to the business.

Porter's five forces model is analyzed to understand the overall competitive scenario that prevails in the market. The SWOT analysis also identifies the positive as well as the negative characteristics of market development which influences the company’s growth and development to sustain and survive in the long run. The PESTEL analysis identifies the macro (external) forces affecting the organization.

The report includes a thorough analysis of the company profiles of major companies operating in the global biosimilars market and a comparative evaluation based on their business overviews, product offering, geographic presence, market share, business strategy, recent developments, product development & innovations, joint ventures, partnerships, mergers & acquisitions, expansions, SWOT analysis, and key financial information. It helps in evaluating the overall competition present in the market scenario.

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Full Name

Company Name

Designation/Position

Contact

Region/Country

Message

Kindly share your specific requirement (if any), so we can get back to you with a solution

TABLE OF CONTENTS
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE
1.4. MARKET DEFINITION
1.5. CURRENCY CONSIDERATION
1.6. YEAR CONSIDERATION
2. RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION
3. EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4. PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS
4.5. MARKET ATTRACTIVENESS ANALYSIS
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS
4.5.1.1. BIOSIMILARS MARKET ATTENTIVENESS BY MANUFACTURING
4.5.1.2. BIOSIMILARS MARKET ATTENTIVENESS BY PRODUCT TYPE
4.5.1.3. BIOSIMILARS MARKET ATTENTIVENESS BY INDICATION
4.5.2. MARKET ATTRACTIVENESS BY REGION
4.5.2.1. NORTH AMERICA BIOSIMILARS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE BIOSIMILARS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC BIOSIMILARS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA BIOSIMILARS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3. PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS
4.9. YEAR ON YEAR GROWTH RATE OF BIOSIMILARS
4.10. LIST OF SUPPLIERS
4.11. LIST OF BUYERS
4.12. COUNTRY LEVEL ANALYSIS
4.13. RULES AND REGULATION
5. MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. INCREASING DEMAND FOR BIOSIMILAR DRUGS
5.1.2. RISING INCIDENCE OF CHRONIC DISEASES
5.2. MARKET RESTRAINTS
5.2.1. UNAVAILABILITY OF DEFINITIVE STANDARDS FOR APPROVAL AND PROFITABILITY
5.2.2. RISKS & CONCERNS REGARDING SUBSTITUTABILITY AND INTERCHANGEABILITY
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6. GLOBAL BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY PRODUCT TYPE - 2017-2028
6.1. KEY FINDINGS
6.2. INSULIN
6.3. INTERFERON
6.4. ETANERCEPT
6.5. INFLIXIMAB
6.6. RITUXIMAB
6.7. GLUCAGON
6.8. CALCITONIN
7. GLOBAL BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY MANUFACTURING - 2017-2028
7.1. KEY FINDINGS
7.2. IN-HOUSE
7.3. CONTRACT
8. GLOBAL BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY INDICATION - 2017-2028
8.1. KEY FINDINGS
8.2. ONCOLOGY
8.3. CHRONIC DISEASE
8.4. BLOOD DISORDER
8.5. AUTOIMMUNE DISEASE
9. GLOBAL BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
9.1. KEY FINDINGS
9.2. NORTH AMERICA
9.3. EUROPE
9.4. ASIA PACIFIC
9.5. SOUTH AMERICA
9.6. MIDDLE EAST & AFRICA
10. NORTH AMERICA BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
10.1. BY COUNTRY
10.1.1. U.S.
10.1.2. CANADA
10.1.3. MEXICO
11. EUROPE BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY
11.1.1. GERMANY
11.1.2. U.K.
11.1.3. FRANCE
11.1.4. ITALY
11.1.5. SPAIN
11.1.6. SWEDEN
11.1.7. BELGIUM
11.1.8. TURKEY
11.1.9. RUSSIA
11.1.10. POLAND
11.1.11. SWITZERLAND
11.1.12. NETHERLANDS
11.1.13. REST OF EUROPE
12. ASIA PACIFIC BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY
12.1.1.1. JAPAN
12.1.1.2. CHINA
12.1.1.3. INDIA
12.1.1.4. AUSTRALIA
12.1.1.5. SOUTH KOREA
12.1.1.6. MALAYSIA
12.1.1.7. INDONESIA
12.1.1.8. VIETNAM
12.1.1.9. NEW ZEALAND
12.1.1.10. PHILIPPINES
12.1.1.11. TAIWAN
12.1.1.12. SINGAPORE
12.1.1.13. REST OF ASIA-PACIFIC
13. SOUTH AMERICA BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY
13.1.1.1. BRAZIL
13.1.1.2. ARGENTINA
13.1.1.3. CHILE
13.1.1.4. COLOMBIA
13.1.1.5. REST OF SOUTH AMERICA
14. MIDDLE EAST & AFRICA BIOSIMILARS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY
14.1.1.1. SOUTH AFRICA
14.1.1.2. U.A.E.
14.1.1.3. SAUDI ARABIA
14.1.1.4. REST OF MIDDLE EAST AND AFRICA
15. COMPETITIVE LANDSCAPE
15.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
15.1.1. GLOBAL MARKET SHARE ANALYSIS
15.1.2. NORTH AMERICA MARKET SHARE ANALYSIS
15.1.3. EUROPE MARKET SHARE ANALYSIS
15.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS
15.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
15.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
15.2. LEADERSHIP MAPPING
15.2.1. VISIONARY PLAYERS
15.2.2. INNOVATORS PLAYERS
15.2.3. DYNAMIC DIFFERENTIATORS
15.2.4. EMERGING COMPANIES
15.3. COMPETITIVE SCENARIO AND TRENDS
15.3.1. MERGERS & ACQUISITIONS
15.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
15.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
15.3.4. EXPANSIONS
16. COMPANY PROFILES
16.1.1. PFIZER
16.1.1.1. COMPANY OVERVIEW
16.1.1.2. COMPANY SNAPSHOT
16.1.1.3. FINANCIAL ANALYSIS
16.1.1.3.1. REVENUE ANALYSIS
16.1.1.3.2. SALES ANALYSIS
16.1.1.3.3. PRICE ANALYSIS
16.1.1.3.4. MARGIN ANALYSIS
16.1.1.4. GEOGRAPHICAL PRESENCE
16.1.1.4.1. NORTH AMERICA
16.1.1.4.2. EUROPE
16.1.1.4.3. ASIA PACIFIC
16.1.1.4.4. SOUTH AMERICA
16.1.1.4.5. MIDDLE EAST & AFRICA
16.1.1.5. PRODUCT PORTFOLIO
16.1.1.6. SWOT ANALYSIS
16.1.1.7. RECENT DEVELOPMENT
16.1.2. SANDOZ
16.1.3. BIOCON
16.1.4. FRESENIUS KABI AG
16.1.5. BOEHRINGER INGELHEIM
16.1.6. MYLAN
16.1.7. ELI LILLY
16.1.8. TEVA PHARMACEUTICAL
16.1.9. DR. REDDY'S LABORATORIES
16.1.10. AMGEN
16.1.11. CELLTRION
16.1.12. SAMSUNG BIOLOGICS
16.1.13. AMEGA BIOTECH
16.1.14. MABXIENCE
16.1.15. PROBIOMED
16.1.16. APOTEX
16.1.17. GEDEON RICHTER
16.1.18. BIOCAD
16.1.19. COHERUS BIOSCIENCE
16.1.20. STADA ARZNEIMITTEL AG
17. STRATEGIC RECOMMENDATIONS
LIST OF TABLE
1. RESEARCH ASSUMPTION
2. COVID-19 IMPACT ON MARKET
3. MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4. GLOBAL BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
5. GLOBAL INSULIN BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6. GLOBAL INTERFERON BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7. GLOBAL ETANERCEPT BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
8. GLOBAL INFLIXIMAB BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9. GLOBAL RITUXIMAB BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
10. GLOBAL GLUCAGON BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
11. GLOBAL CALCITONIN BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
12. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
13. GLOBAL IN-HOUSE BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
14. GLOBAL CONTRACT BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
15. GLOBAL BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
16. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
17. GLOBAL CHRONIC DISEASE BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
18. GLOBAL BLOOD DISORDER BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
19. GLOBAL AUTOIMMUNE DISEASE BIOSIMILARS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
20. GLOBAL BIOSIMILARS MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
21. NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
22. NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
23. NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
24. U.S. BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
25. U.S. BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
26. U.S. BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
27. CANADA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
28. CANADA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
29. CANADA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
30. MEXICO BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
31. MEXICO BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
32. MEXICO BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
33. EUROPE BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
34. EUROPE BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
35. EUROPE BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
36. GERMANY BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
37. GERMANY BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
38. GERMANY BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
39. FRANCE BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
40. FRANCE BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
41. FRANCE BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
42. U.K. BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
43. U.K. BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
44. U.K. BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
45. ITALY BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
46. ITALY BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
47. ITALY BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
48. SPAIN BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
49. SPAIN BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
50. SPAIN BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
51. SWEDEN BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
52. SWEDEN BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
53. SWEDEN BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
54. BELGIUM BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
55. BELGIUM BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
56. BELGIUM BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
57. TURKEY BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
58. TURKEY BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
59. TURKEY BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
60. RUSSIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
61. RUSSIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
62. RUSSIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
63. POLAND BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
64. POLAND BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
65. POLAND BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
66. SWITZERLAND BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
67. SWITZERLAND BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
68. SWITZERLAND BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
69. NETHERLANDS BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
70. NETHERLANDS BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
71. NETHERLANDS BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
72. ASIA PACIFIC BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
73. ASIA PACIFIC BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
74. ASIA PACIFIC BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
75. JAPAN BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
76. JAPAN BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
77. JAPAN BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
78. CHINA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
79. CHINA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
80. CHINA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
81. INDIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
82. INDIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
83. INDIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
84. AUSTRALIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
85. AUSTRALIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
86. AUSTRALIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
87. SOUTH KOREA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
88. SOUTH KOREA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
89. SOUTH KOREA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
90. INDONESIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
91. INDONESIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
92. INDONESIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
93. VIETNAM BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
94. VIETNAM BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
95. VIETNAM BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
96. NEW ZEALAND BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
97. NEW ZEALAND BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
98. NEW ZEALAND BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
99. PHILIPPINES BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
100. PHILIPPINES BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
101. PHILIPPINES BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
102. TAIWAN BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
103. TAIWAN BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
104. TAIWAN BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
105. SINGAPORE BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
106. SINGAPORE BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
107. SINGAPORE BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
108. SOUTH AMERICA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
109. SOUTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
110. SOUTH AMERICA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
111. BRAZIL BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
112. BRAZIL BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
113. BRAZIL BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
114. ARGENTINA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
115. ARGENTINA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
116. ARGENTINA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
117. CHILE BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
118. CHILE BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
119. CHILE BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
120. COLOMBIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
121. COLOMBIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
122. COLOMBIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
123. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
124. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
125. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
126. UAE BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
127. UAE BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
128. UAE BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
129. SOUTH AFRICA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
130. SOUTH AFRICA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
131. SOUTH AFRICA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
132. SAUDI ARABIA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
133. SAUDI ARABIA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
134. SAUDI ARABIA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)
135. REST OF MEA BIOSIMILARS MARKET, BY PRODUCT TYPE, 2017–2028 REVENUE (USD MILLION)
136. REST OF MEA BIOSIMILARS MARKET, BY MANUFACTURING, 2017–2028 REVENUE (USD MILLION)
137. REST OF MEA BIOSIMILARS MARKET, BY INDICATION, 2017–2028 REVENUE (USD MILLION)

LIST OF FIGURE
1. RESEARCH DESIGN
2. SCOPE OF THE STUDY
3. GEOGRAPHIC SCOPE
4. CURRENCY CONSIDERATION
5. YEAR CONSIDERATION
6. MARKET ESTIMATION
7. RESEARCH METHODOLOGY
8. DATA TRIANGULATION
9. COVID-19 IMPACT ON MARKET
10. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS ANALYSIS BY MANUFACTURING
11. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS ANALYSIS BY PRODUCT TYPE
12. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS ANALYSIS BY INDICATION
13. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS ANALYSIS BY REGION
14. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
15. GLOBAL BIOSIMILARS MARKET: DYNAMICS
16. PESTEL ANALYSIS
17. SWOT ANALYSIS
18. GLOBAL BIOSIMILARS MARKET ANALYSIS BY REGION
19. GLOBAL BIOSIMILARS MARKET ANALYSIS BY MANUFACTURING
20. GLOBAL BIOSIMILARS MARKET ANALYSIS BY PRODUCT TYPE
21. GLOBAL BIOSIMILARS MARKET ANALYSIS BY INDICATION
22. GLOBAL BIOSIMILARS MARKET ANALYSIS BY NORTH AMERICA
23. GLOBAL BIOSIMILARS MARKET ANALYSIS BY EUROPE
24. GLOBAL BIOSIMILARS MARKET ANALYSIS BY ASIA PACIFIC
25. GLOBAL BIOSIMILARS MARKET ANALYSIS BY SOUTH AMERICA
26. GLOBAL BIOSIMILARS MARKET ANALYSIS BY MIDDLE EAST & AFRICA
27. GLOBAL BIOSIMILARS MARKET SHARE BY COMPANY (2020)
28. NORTH AMERICA BIOSIMILARS MARKET SHARE BY COMPANY (2020)
29. EUROPE BIOSIMILARS MARKET SHARE BY COMPANY (2020)
30. ASIA PACIFIC BIOSIMILARS MARKET SHARE BY COMPANY (2020)
31. SOUTH AMERICA BIOSIMILARS MARKET SHARE BY COMPANY (2020)
32. MIDDLE EAST & AFRICA BIOSIMILARS MARKET SHARE BY COMPANY (2020)